Single Variable-Domain Binding to Distinguish Plasmin-Cleaved VWF
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to distinguish between different proteolytic cleavage products of von Willebrand factor (VWF), particularly plasmin-cleaved VWF, hindering the study of its pathological roles.
Innovation Solution
Development of single variable domain antibodies with specific CDR sequences that exhibit high affinity for plasmin-cleaved VWF, allowing discrimination from intact and ADAMTS13-cleaved VWF.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used, then general VWF detection is possible, but discrimination between different proteolytic cleavage products (plasmin-cleaved vs. ADAMTS13-cleaved vs. intact VWF) cannot be achieved
Solution Approach 1:
The invention segments the detection capability by providing three distinct single domain antibodies, each specifically recognizing one type of VWF cleavage product (intact, plasmin-cleaved, or ADAMTS13-cleaved). This segmentation allows precise discrimination of different VWF forms without requiring complex multi-step procedures, as each antibody can be used independently for its specific detection purpose.
Solution Approach 2:
The single domain antibodies serve as intermediaries that bridge the gap between the different VWF cleavage products and the detection system. Each antibody acts as a specific mediator that binds to its target epitope, enabling the detection system to distinguish between intact VWF, plasmin-cleaved VWF, and ADAMTS13-cleaved VWF through simple binding assays.
2Reliability
If high specificity for plasmin-cleaved VWF is achieved through specialized antibody design, then accurate detection of plasmin-cleaved VWF becomes possible, but the complexity of antibody development and characterization increases
Solution Approach 1:
The invention extracts the essential antigen-binding function from conventional antibodies by using only the single variable domain (VH or VL). This extraction maintains the specificity and affinity required for reliable plasmin-cleaved VWF detection while simplifying the antibody structure, reducing development complexity, and enabling easier production and characterization compared to full-length antibodies.
Solution Approach 2:
The invention changes the structural parameters of the antibody by reducing it from a full-length complex structure to a single domain format. This parameter change maintains the critical binding properties (specificity and affinity) while simplifying the overall molecular complexity, making the antibody easier to produce, purify, and characterize for reliable plasmin-cleaved VWF detection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate detection and quantification of plasmin-cleaved VWF, facilitating the assessment of vascular events and therapeutic agent efficacy.
Implementation Method 1
The present invention relates to single antibody domains, especially single antibody domains that specifically bind plasmin-cleaved von Willebrand factor (VWF)
Data Source
AI summary
The present invention relates to single antibody domains, especially single antibody domains that specifically bind plasmin-cleaved von Willebrand factor (VWF). The invention further relates a method for detecting plasmin-cleaved VWF. This method further allows for the determining the activity of a therapeutic agent regulating plasmin-mediated cleavage of VWF, or the determination of a vascular event in a subject. The invention further describes kits comprising these single antibody domains.